Lowers time from preparation to finish for patients with Alpha-1 Antitrypsin Deficiency by more than 75%
Preliminary human and animal studies indicate that AAT may considerably reduce the severity of GVHD, which is one of the key, life threatening complications of allogeneic stem cell transplantation.
NESS ZIONA, Israel (March 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema). This trial is […]
Affirms plans for EMA submission in the second half of 2014
NESS ZIONA, Israel (March 5, 2014) – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D). In T1D, autoimmune attacks occur […]
NESS ZIONA, Israel (March 4, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB® as a post-exposure prophylaxis (PEP) for rabies. KamRAB is Kamada's human rabies immune globulin, currently marketed for this […]
NESS ZIONA, Israel (February 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will ring the Opening Bell at The NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Tuesday, February 25, 2014. David Tsur, Co-Founder and Chief Executive […]
Total revenue for the fourth quarter of 2013 increased 13% to $24.4 million from $21.6 million for the fourth quarter of 2012, reflecting higher revenue in the Proprietary Products Segment. Total revenue increased 40% compared with the third quarter of 2013.
Fourth quarter proprietary products revenues posted a record high of $18.6 million
Expects top-line data from European Phase 2/3 trial of inhaled AAT for AATD in 1Q and
initiation of two important clinical trials in coming weeks
Conference call begins today at 8:30 a.m. Eastern time
Kamada management will host an investment community conference call on Wednesday, February 5, 2014 beginning at 8:30 a.m. Eastern time